Conserved Type III Secretion System Exerts Important Roles in Chlamydia Trachomatis

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2014 Oct 23

PMID 25337183

Citations 15

Authors

Wenting Dai

Zhongyu Li

Affiliations

Soon will be listed here.

Abstract

Upon infection, Chlamydiae alter host cellular functions in a variety of ways. Chlamydial infection prevents host cell apoptosis, induces re-organization of the actin cytoskeleton and alters host cellular signaling mechanisms. Chlamydia is among the many pathogenic Gram-negative bacteria that employ the type III secretion system (T3SS) to overcome host defenses and exploit available resources. T3SS are used by many Gram-negative bacterial pathogens to manipulate eukaryotic host cells through the delivery of effector proteins into their cytosol and membranes. T3SS is an evolutionarily refined, virulence determinant of Gram-negative bacteria where more than 20 proteins form an apparatus, generally termed injectisome, to achieve the vectorial secretion and translocation of anti-host effector proteins. This review describes challenges and recent advances that have revealed how Chlamydia trachomatis utilizes diversification to produce a conserved T3SS that exerts an important role in Chlamydia trachomatis.

Citing Articles

Identification and Preliminary Characterization of Novel Type III Secreted Effector Proteins in Chlamydia trachomatis.

McCaslin P, Andersen S, Icardi C, Faris R, Steiert B, Smith P Infect Immun. 2023; 91(7):e0049122.

PMID: 37347192 PMC: 10353436. DOI: 10.1128/iai.00491-22.

[Type III secretory protein SINC of promotes host cell autophagy by activating the MAPK/ERK signaling pathway].

Zeng X, Zhou P, Tang T, Chen X, Hu D, Wang C Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(2):294-299.

PMID: 36946051 PMC: 10034536. DOI: 10.12122/j.issn.1673-4254.2023.02.19.

Requires Functional Host-Cell Mitochondria and NADPH Oxidase 4/p38MAPK Signaling for Growth in Normoxia.

Thapa J, Yoshiiri G, Ito K, Okubo T, Nakamura S, Furuta Y Front Cell Infect Microbiol. 2022; 12:902492.

PMID: 35719337 PMC: 9199516. DOI: 10.3389/fcimb.2022.902492.

Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.

Hotinger J, Pendergrass H, May A Biomolecules. 2021; 11(2).

PMID: 33669653 PMC: 7922566. DOI: 10.3390/biom11020316.

A 2-pyridone amide inhibitor of transcriptional activity in .

Nunez-Otero C, Bahnan W, Vielfort K, Silver J, Singh P, Elbir H Antimicrob Agents Chemother. 2021; 95(5).

PMID: 33593835 PMC: 8092867. DOI: 10.1128/AAC.01826-20.

References

Hower S, Wolf K, Fields K . Evidence that CT694 is a novel Chlamydia trachomatis T3S substrate capable of functioning during invasion or early cycle development. Mol Microbiol. 2009; 72(6):1423-37. PMC: 2997736. DOI: 10.1111/j.1365-2958.2009.06732.x. View

Cornelis G . The type III secretion injectisome. Nat Rev Microbiol. 2006; 4(11):811-25. DOI: 10.1038/nrmicro1526. View

Brinkworth A, Malcolm D, Pedrosa A, Roguska K, Shahbazian S, Graham J . Chlamydia trachomatis Slc1 is a type III secretion chaperone that enhances the translocation of its invasion effector substrate TARP. Mol Microbiol. 2011; 82(1):131-44. PMC: 3214626. DOI: 10.1111/j.1365-2958.2011.07802.x. View

Gong S, Lei L, Chang X, Belland R, Zhong G . Chlamydia trachomatis secretion of hypothetical protein CT622 into host cell cytoplasm via a secretion pathway that can be inhibited by the type III secretion system inhibitor compound 1. Microbiology (Reading). 2011; 157(Pt 4):1134-1144. PMC: 3139441. DOI: 10.1099/mic.0.047746-0. View

da Cunha M, Milho C, Almeida F, Pais S, Borges V, Mauricio R . Identification of type III secretion substrates of Chlamydia trachomatis using Yersinia enterocolitica as a heterologous system. BMC Microbiol. 2014; 14:40. PMC: 3931295. DOI: 10.1186/1471-2180-14-40. View

Derre I, Swiss R, Agaisse H . The lipid transfer protein CERT interacts with the Chlamydia inclusion protein IncD and participates to ER-Chlamydia inclusion membrane contact sites. PLoS Pathog. 2011; 7(6):e1002092. PMC: 3121800. DOI: 10.1371/journal.ppat.1002092. View

Saka H, Thompson J, Chen Y, Kumar Y, Dubois L, Moseley M . Quantitative proteomics reveals metabolic and pathogenic properties of Chlamydia trachomatis developmental forms. Mol Microbiol. 2011; 82(5):1185-203. PMC: 3225693. DOI: 10.1111/j.1365-2958.2011.07877.x. View

Francis M, Wolf-Watz H, Forsberg A . Regulation of type III secretion systems. Curr Opin Microbiol. 2002; 5(2):166-72. DOI: 10.1016/s1369-5274(02)00301-6. View

Dumoux M, Clare D, Saibil H, Hayward R . Chlamydiae assemble a pathogen synapse to hijack the host endoplasmic reticulum. Traffic. 2012; 13(12):1612-27. PMC: 3533787. DOI: 10.1111/tra.12002. View

10.

Pennini M, Perrinet S, Dautry-Varsat A, Subtil A . Histone methylation by NUE, a novel nuclear effector of the intracellular pathogen Chlamydia trachomatis. PLoS Pathog. 2010; 6(7):e1000995. PMC: 2904774. DOI: 10.1371/journal.ppat.1000995. View

11.

Subtil A, Blocker A, Dautry-Varsat A . Type III secretion system in Chlamydia species: identified members and candidates. Microbes Infect. 2000; 2(4):367-9. DOI: 10.1016/s1286-4579(00)00335-x. View

12.

Omsland A, Sager J, Nair V, Sturdevant D, Hackstadt T . Developmental stage-specific metabolic and transcriptional activity of Chlamydia trachomatis in an axenic medium. Proc Natl Acad Sci U S A. 2012; 109(48):19781-5. PMC: 3511728. DOI: 10.1073/pnas.1212831109. View

13.

Muschiol S, Normark S, Henriques-Normark B, Subtil A . Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells. BMC Microbiol. 2009; 9:75. PMC: 2679026. DOI: 10.1186/1471-2180-9-75. View

14.

Spaeth K, Chen Y, Valdivia R . The Chlamydia type III secretion system C-ring engages a chaperone-effector protein complex. PLoS Pathog. 2009; 5(9):e1000579. PMC: 2734247. DOI: 10.1371/journal.ppat.1000579. View

15.

Le Negrate G, Krieg A, Faustin B, Loeffler M, Godzik A, Krajewski S . ChlaDub1 of Chlamydia trachomatis suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol. 2008; 10(9):1879-92. DOI: 10.1111/j.1462-5822.2008.01178.x. View

16.

Wang J, Chen L, Chen F, Zhang X, Zhang Y, Baseman J . A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine. 2009; 27(22):2967-80. PMC: 2680781. DOI: 10.1016/j.vaccine.2009.02.095. View

17.

Mital J, Miller N, Fischer E, Hackstadt T . Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network. Cell Microbiol. 2010; 12(9):1235-49. PMC: 2923664. DOI: 10.1111/j.1462-5822.2010.01465.x. View

18.

Samudrala R, Heffron F, McDermott J . Accurate prediction of secreted substrates and identification of a conserved putative secretion signal for type III secretion systems. PLoS Pathog. 2009; 5(4):e1000375. PMC: 2668754. DOI: 10.1371/journal.ppat.1000375. View

19.

Thomas N, Ma I, Prasad M, Rafuse C . Expanded roles for multicargo and class 1B effector chaperones in type III secretion. J Bacteriol. 2012; 194(15):3767-73. PMC: 3416526. DOI: 10.1128/JB.00406-12. View

20.

Betts H, Twiggs L, Sal M, Wyrick P, Fields K . Bioinformatic and biochemical evidence for the identification of the type III secretion system needle protein of Chlamydia trachomatis. J Bacteriol. 2008; 190(5):1680-90. PMC: 2258694. DOI: 10.1128/JB.01671-07. View